Celyad SA is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T NKR-2, C-Cure. The firm has CYAD-01, CYAD-02, CYAD-03 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments. It derives majority of its revenues from Immuno-oncology segment.
| Website: | www.celyad.com |
| Email: | investors@celyad.com |
| Main Phone: | +32 10394100 |
| Address: | Rue Edouard Belin 2 |
| City / Town: | Mont-Saint-Guibert |
| Country: | BEL |
| Postal Code: | 1435 |
| Exchange: | NSD |
| CEO: | Filippo Petti |
| Employees: | 96 |
Gathering Data... Please wait Celyad SA is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T NKR-2, C-Cure. The firm has CYAD-01, CYAD-02, CYAD-03 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments. It derives majority of its revenues from Immuno-oncology segment.
| Website: | www.celyad.com |
| Email: | investors@celyad.com |
| Main Phone: | +32 10394100 |
| Address: | Rue Edouard Belin 2 |
| City / Town: | Mont-Saint-Guibert |
| Country: | BEL |
| Postal Code: | 1435 |
| Exchange: | NSD |
| CEO: | Filippo Petti |
| Employees: | 96 |
| Last Price 13.35 | Change $ -5.41 | Change % -28.84 | Tick N/A |
| Bid 13.35 | Bid Size 100.00 | Ask 13.59 | Ask Size 900.00 |
| Open 14.37 | High 14.74 | Low 13.00 | Prev Close 18.76 |
| Last Trade | Volume 33,384 | 52 Wk Hi 32.18 | 52 Wk Low 15.36 |
| Market Cap 159.4 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 11,942,344.00 | EPS (TTM) -3.86 | PE Ratio N/A | Exchange NSD |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 74 | 74 | 74 | 74 |
| Low Target Price Estimate | 49 | 74 | 74 | 49 |
| Mean Target Price Estimate | 61.5 | 74 | 74 | 61.5 |
| Standard Deviation | 17.68 | 0 | 0 | 17.68 |
| Date of Most Recent Estimate | 05/31/18 | 03/23/18 | 03/23/18 | 05/31/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 7 | 2018-05-23 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 58 | 2018-05-18 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 109 | 2018-05-18 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 8 | 2018-05-16 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 109 | 2018-05-16 |
| FWP | Free Writing Prospectus | 4 | 2018-05-16 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 37 | 2018-05-11 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 12 | 2018-05-03 |
| 20-F | Annual and transition report of foreign private issuers under sections 13 or 15(d) | 221 | 2018-04-06 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 17 | 2018-03-23 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 3 | 1 | 1 | 1 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
